Skip to main content

Advertisement

Table 3 Surface under the cumulative ranking curve (SUCRA) data for the outcomes of mortality and severe adverse events

From: Treatment of idiopathic pulmonary fibrosis: a network meta-analysis

a. SUCRA rankings for mortality
Treatment SUCRA
Sildenafil 0.913
Pirfenidone 0.749
Nintedanib 0.719
Imatinib 0.624
Macitentan 0.604
Bosentan 0.533
Placebo 0.490
NAC monotherapy 0.483
Ambrisentan 0.238
VKA 0.097
Triple therapy 0.050
b. SUCRA rankings for severe adverse events
Treatment SUCRA
Bosentan 0.756
Sildenafil 0.692
Macitentan 0.684
Nintedanib 0.638
Imatinib 0.627
Pirfenidone 0.597
Placebo 0.587
NAC monotherapy 0.413
Ambrisentan 0.279
VKA 0.190
Triple therapy 0.038
  1. SUCRA, Surface under cumulative ranking curve